NYSE:TAKTakeda Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.58 +0.18 (+0.98 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$18.48Now: $18.58▼$18.7150-Day Range$16.51MA: $18.22▼$19.5052-Week Range$12.43Now: $18.58▼$20.92Volume1.21 million shsAverage Volume1.08 million shsMarket Capitalization$58.58 billionP/E Ratio132.72Dividend Yield1.63%Beta1.02 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesOptions ChainSocial Media Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingTakeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Takeda Pharmaceutical has a potential upside of 33.2% from its current price of $18.58.Amount of Analyst CoverageTakeda Pharmaceutical has only been the subject of 1 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesTakeda Pharmaceutical has received 88 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTakeda Pharmaceutical has received 120 “underperform” votes. (Add your “underperform” vote.)Community SentimentTakeda Pharmaceutical has received 57.69% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote “Outperform” if you believe TAK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TAK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 3.3 Dividend Strength Dividend LeadershipTakeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 1.63%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTakeda Pharmaceutical has only been increasing its dividend for 2 years.Dividend CoverageThe dividend payout ratio of Takeda Pharmaceutical is 16.85 %. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 13.51 % next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 3.67% of the stock of Takeda Pharmaceutical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Takeda Pharmaceutical are expected to grow by 8.82% in the coming year, from $2.04 to $2.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Takeda Pharmaceutical is 132.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Takeda Pharmaceutical is 132.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.75.Price to Book Value per Share RatioTakeda Pharmaceutical has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.1Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.86 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TAK Previous Symbol CUSIPN/A CIKN/A Webwww.takeda.com Phone813-3278-2306Debt Debt-to-Equity Ratio0.95 Current Ratio1.13 Quick Ratio0.79Price-To-Earnings Trailing P/E Ratio132.72 Forward P/E Ratio9.11 P/E GrowthN/A Sales & Book Value Annual Sales$30.20 billion Price / Sales1.94 Cash Flow$3.49 per share Price / Cash Flow5.32 Book Value$13.80 per share Price / Book1.35Profitability EPS (Most Recent Fiscal Year)$1.78 Net Income$407.02 million Net Margins1.37% Return on Equity13.80% Return on Assets5.11%Miscellaneous Employees49,578 Outstanding Shares3,152,750,000Market Cap$58.58 billion Next Earnings Date7/29/2020 (Estimated) OptionableOptionable TAK Rates by TradingView Receive TAK News and Ratings via Email Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions How has Takeda Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TAK shares have increased by 8.3% and is now trading at $18.58. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Takeda Pharmaceutical? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Takeda Pharmaceutical. When is Takeda Pharmaceutical's next earnings date? Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Takeda Pharmaceutical. How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co Ltd (NYSE:TAK) issued its quarterly earnings results on Wednesday, May, 13th. The company reported $0.13 EPS for the quarter. The company had revenue of $7.09 billion for the quarter. Takeda Pharmaceutical had a net margin of 1.37% and a return on equity of 13.80%. View Takeda Pharmaceutical's earnings history. What price target have analysts set for TAK? 4 brokerages have issued twelve-month price objectives for Takeda Pharmaceutical's stock. Their forecasts range from $19.50 to $30.00. On average, they expect Takeda Pharmaceutical's stock price to reach $24.75 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View analysts' price targets for Takeda Pharmaceutical. Has Takeda Pharmaceutical been receiving favorable news coverage? News coverage about TAK stock has been trending positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Takeda Pharmaceutical earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutTakeda Pharmaceutical. Who are some of Takeda Pharmaceutical's key competitors? Some companies that are related to Takeda Pharmaceutical include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Vertex Pharmaceuticals (VRTX) and Bayer (BAYRY). View all competitors. What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Verizon Communications (VZ), Johnson & Johnson (JNJ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T), Abbott Laboratories (ABT) and Walt Disney (DIS). Who are Takeda Pharmaceutical's key executives? Takeda Pharmaceutical's management team includes the following people: Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)Dr. Seigo Izumo M.D., Chair of Management BoardMr. Costa Saroukos, Chief Financial Officer (Age 48)Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62) What is Takeda Pharmaceutical's stock symbol? Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK." Who are Takeda Pharmaceutical's major shareholders? Takeda Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Adelphi Capital LLP (0.29%), Mondrian Investment Partners LTD (0.11%), Parametric Portfolio Associates LLC (0.11%), Morgan Stanley (0.05%), Morgan Stanley (0.05%) and First Trust Advisors LP (0.05%). Which institutional investors are selling Takeda Pharmaceutical stock? TAK stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Janus Henderson Group PLC, Voloridge Investment Management LLC, Deutsche Bank AG, Aperio Group LLC, Mondrian Investment Partners LTD, Cinctive Capital Management LP, and Parametric Portfolio Associates LLC. Which institutional investors are buying Takeda Pharmaceutical stock? TAK stock was purchased by a variety of institutional investors in the last quarter, including NWQ Investment Management Company LLC, Morgan Stanley, Morgan Stanley, Adelphi Capital LLP, Managed Asset Portfolios LLC, Raymond James & Associates, JPMorgan Chase & Co., and Avalon Investment & Advisory. How do I buy shares of Takeda Pharmaceutical? Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Takeda Pharmaceutical's stock price today? One share of TAK stock can currently be purchased for approximately $18.58. How big of a company is Takeda Pharmaceutical? Takeda Pharmaceutical has a market capitalization of $58.58 billion and generates $30.20 billion in revenue each year. The company earns $407.02 million in net income (profit) each year or $1.78 on an earnings per share basis. Takeda Pharmaceutical employs 49,578 workers across the globe. What is Takeda Pharmaceutical's official website? The official website for Takeda Pharmaceutical is www.takeda.com. How can I contact Takeda Pharmaceutical? Takeda Pharmaceutical's mailing address is 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo M0, 103-8668. The company can be reached via phone at 813-3278-2306. This page was last updated on 6/6/2020 by MarketBeat.com Staff
